Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.2421
-0.0016-0.66%
Post-market: 0.2400-0.0021-0.87%19:00 EST
Volume:1.07M
Turnover:260.10K
Market Cap:29.73M
PE:-1.06
High:0.2480
Open:0.2404
Low:0.2335
Close:0.2437
52wk High:0.9400
52wk Low:0.2335
Shares:122.80M
Float Shares:89.14M
Volume Ratio:0.68
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2288
EPS(LYR):-0.3117
ROE:-730.06%
ROA:-148.34%
PB:-0.86
PE(LYR):-0.78

Loading ...

Press Release: VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Dow Jones
·
Nov 14

VolitionRX Ltd. Issues Correction to November 7 SEC Filing

Reuters
·
Nov 14

VolitionRx Issues Amended 8-K to Replace Exhibit in SEC Filing

Reuters
·
Nov 11

VolitionRX Ltd. to Announce Third Quarter 2025 Results

Reuters
·
Nov 10

VolitionRX Amends Underwriting Agreement for Stock Offering

TIPRANKS
·
Nov 08

Volition Donates Nu.q® Vet Cancer Tests to Hope Animal-Assisted Crisis Response Dogs

THOMSON REUTERS
·
Oct 17

VolitionRX Executives Make Bold Moves with Major Stock Purchases!

TIPRANKS
·
Oct 16

VolitionRX Ltd. Director Timothy I. Still Reports Acquisition of Common Shares

Reuters
·
Oct 16

VolitionRX Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

THOMSON REUTERS
·
Oct 10

BRIEF-Volitionrx Limited Announces Proposed Underwritten Public Offering Of Common Stock

Reuters
·
Oct 10

VolitionRX Ltd announces proposed underwritten public offering of common stock and warrants

Reuters
·
Oct 10

VolitionRx Ltd. to Sponsor GenomeWeb Webinar Showcasing Epigenetic Profiling Innovations

Reuters
·
Oct 02

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 30

BRIEF-Volition Signs Co-Marketing And Services Agreement With Hologic

Reuters
·
Sep 29

VolitionRx signs co-marketing and services agreement with Hologic

TIPRANKS
·
Sep 29

VolitionRX: Hologic to Co-Market Nu.q Discover Services of Volition With Hologic Customers for Initial One-Year Term

THOMSON REUTERS
·
Sep 29

VolitionRX Ltd. CEO Cameron John Reynolds Reports Acquisition of Common Shares

Reuters
·
Sep 15

VolitionRX Ltd. Unveils Corporate Deck Highlighting Innovations in Low-Cost Cancer and Sepsis Testing

Reuters
·
Sep 11

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 10

BRIEF-Volition Signs First Human Out Licensing Deal

Reuters
·
Sep 09